Technology | October 20, 2011

GE Healthcare Highlights Latest Nuclear Imaging Technology at RSNA 2011

GE Healthcare looks to the future of molecular imaging through improving cost, quality and access by helping clinicians deliver responsible care, both clinically and economically. This includes a focus on positron emission tomography (PET) treatment assessment, reinforced by a portfolio of quantitative imaging tools to help clinicians detect, diagnose and monitor disease earlier, and to evaluate cancer treatment efficacy more quickly.

GE Healthcare has created Q.Suite, a collection of next-generation capabilities designed to further quantitative PET by generating more, consistent standard uptake values readings — and enabling clinicians to assess treatment response more accurately than ever before.

In nuclear medicine, GE will showcase innovative and advanced technology, specifically the Discovery NM/CT 670, designed to improve workflow, dose management, and overall image quality.

The Discovery NM/CT 670 system combines a newly designed SPECT gantry and GE Healthcare’s latest advancements in nuclear medicine detectors with GE Healthcare’s BrightSpeed Elite 16 slice computed tomography (CT), resulting in shorten acquisition times and enabling more convenient patient scheduling in comparison to separate, conventional single photom emission computed tomography (SPECT) and CT exams. With the Discovery NM/CT 670, the imaging time can be reduced from an average of 35 minutes to as little as 16 minutes. After a successful global launch, the system has been selected by 100 sites around the world. The new GE Healthcare Discovery NM630 is engineered to help accommodate more patients than previous generation GE nuclear medicine systems. With its wide bore and table capable of handling patients up to 500 pounds.

Brivo NM615 will make its global debut at RSNA. Brivo NM615, an advanced nuclear medicine gamma camera, is made possible through GE’s innovative Evolution technology. This single head system has the ability to achieve shortened scan times, rivaling a dual head system. Both Discovery systems include SPECT capability that gives doctors the ability to lower injected patient dose by as much as 50 percent of those of standard nuclear medicine scanning protocols, or the potential for patients to spend significantly less time on the table during exams, without compromising image quality.

Also to be showcased:

• Discovery MB750b, a molecular breast imaging system that may assist in assessment and early detection of breast cancer in women who are at high risk for the disease.

• Alcyone technology, adopted by more than 100 leading clinicians worldwide, has become an accepted technology for nuclear cardiology diagnosis. Harnessing four advanced nuclear imaging innovations, Alcyone technology has the ability to reduce scan time and/or injected dose while maintaining image quality. Alcyone technology is available on the Discovery NM 530c.

For more information: www.gehealthcare.com

 

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init